



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

20 January 2020

TAIWAN FDA APPROVAL GRANTED FOR PRIZMA

- **Prizma device granted approval by Taiwan Food and Drug Administration**
- **Major milestone for GMV – allows Company to progress Taiwan market entry**
- **Commercial negotiations can now commence with G Medical's existing partners**
- **GMV to pursue additional opportunities in Taiwan to unlock shareholder value**

Mobile and e-Health company **G Medical Innovations Holdings Limited (ASX:GMV)** ("**G Medical**" "**the Company**"), is pleased to advise that it has received notification through its partner First Channel Ltd ("**FCL**"), that the Company's Prizma medical device has been granted regulatory approval by the Taiwan Food and Drug Administration ("**FDA**").

FCL has until 4 April 2020 to provide the FDA with ancillary Prizma product information (including packaging and labelling) to allow for collection of the permit license in respect of the granted FDA regulatory approval ("**Permit License**").

In accordance with the existing non-exclusive Memorandum of Understanding (**MOU**) between the Company and FCL (collectively "**the Parties**"), the Parties will commence negotiations in good faith, in order to execute a binding agreement to detail specific matters surrounding the distribution and services level requirements (including but not limited to distribution partners, cloud services, call centre operations, end-customer solutions) for the Prizma within Taiwan (refer previous announcements including that dated 10 November 2017).

The Parties have commenced discussions to delineate commercial strategies for the Taiwanese market. As previously advised by the Company, the distribution of the Company's medical products by FCL remains subject to FCL finalising and entering into additional definitive agreements with FCL's third party partners.

G Medical intends to explore additional partnerships within Taiwan. The Company looks forward to updating its shareholders as further details become available.

CEO and Executive Director Dr Yacov Geva said: "Being granted approval by the Taiwan Food and Drug Administration is a tremendous achievement for G Medical. The process has involved rigorous testing, which has outlined the safety and effectiveness of the Prizma device.

"We will work collaboratively with FCL to assist in the final steps towards receiving the Permit License.

"The Company will remain in discussions with FCL regarding a commercial strategy for the region, as well as assess additional opportunities where applicable. Management look forward to updating shareholders as discussions progress."

Authorised for release by Dr Yacov Geva, CEO and Managing Director of the Company.

Ends

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.